Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „avelumab“
Suchtreffer
Begriffe & Kennungen
Bavencio · 4.5 · Avelumab is primarily metabolised through catabolic pathways, therefore, it is not expected that avelumab will
Eintrag öffnenBavencio · 4.5 · No interaction studies have been conducted with avelumab.
Eintrag öffnenBavencio · 4.8 · 14 In patients treated with avelumab in combination with axitinib, 0.6% (3/489) of patients developed immune-m
Eintrag öffnenBavencio · 4.8 · 16 In patients treated with avelumab in combination with axitinib, 1.8% (9/489) of patients developed immune-m
Eintrag öffnenBavencio · 4.8 · 17 Immune-mediated nephritis did not lead to discontinuation of avelumab in any patient. All 2 patients with i
Eintrag öffnenBavencio · 4.8 · Adrenal insufficiency In patients treated with avelumab as monotherapy, 0.5% (11/2 082) of patients developed
Eintrag öffnenBavencio · 4.8 · Among the 73 patients who were rechallenged with either avelumab (59%) or axitinib (85%) monotherapy or with b
Eintrag öffnenBavencio · 4.8 · Avelumab is associated with immune-mediated adverse reactions. Most of these, including severe reactions, reso
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.1% (2/2 082) of patients due to Type 1 diabetes mellitus. Type 1 diabetes melli
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.1% (2/2 082) of patients due to immune-mediated adrenal insufficiency. All 11 p
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (1/489) of patients due to Type 1 diabetes mellitus. All 5 patients with Typ
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (1/489) of patients due to immune-mediated thyroid disorders. Thyroid disord
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (4/2 082) of patients due to immune-mediated nephritis. All 7 patients with
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (4/2 082) of patients due to immune-mediated thyroid disorders. Thyroid diso
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.4% (2/489) of patients due to immune-mediated colitis. All 13 patients with imm
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.4% (9/2 082) of patients due to immune-mediated pneumonitis. All 28 patients wi
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.5% (11/2 082) of patients due to immune-mediated colitis. All 31 patients with
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.6% (13/2 082) of patients due to immune-mediated hepatitis. All 21 patients wit
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 4.7% (23/489) of patients due to immune-mediated hepatitis. All 31 patients with
Eintrag öffnenBavencio · 4.8 · Data for immune-mediated adverse reactions for avelumab as a monotherapy are based on 2 082 patients including
Eintrag öffnen